Medications for Invasive Pulmonary Aspergillosis

11 results
Fosun Pharma USA Inc.
Usage: Caspofungin acetate is indicated for empirical treatment of presumed fungal infections in febrile, neutropenic patients, and for treating candidemia, various Candida infections, esophageal candidiasis, and invasive aspergillosis in patients intolerant to other therapies, with specific limitations for certain conditions.
Areva Pharmaceuticals
Usage: Caspofungin acetate is indicated for empirical therapy of presumed fungal infections in febrile, neutropenic patients, treatment of candidemia and other Candida infections, esophageal candidiasis, and invasive aspergillosis in patients intolerant to other therapies. It is not approved for certain conditions like oropharyngeal candidiasis or initial invasive aspergillosis therapy.
Gland Pharma Limited
Usage: Caspofungin acetate is indicated for the empirical treatment of presumed fungal infections in febrile, neutropenic patients, treatment of candidemia, esophageal candidiasis, and invasive aspergillosis in patients intolerant to other therapies, in adults and pediatric patients aged 3 months and older. Limitations apply for specific infections.

Cresemba (isavuconazonium sulfate)

(isavuconazonium sulfate)
Astellas Pharma US, Inc.
Usage: CRESEMBA is indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adults and pediatric patients, with different age and weight requirements for injection and capsule formulations. Prior laboratory tests to identify the causative organisms should be conducted before starting therapy.
Par Pharmaceutical Inc.
Usage: Posaconazole delayed-release tablets are indicated for treating invasive aspergillosis in patients aged 13 and older. It also prophylaxes invasive Aspergillus and Candida infections in severely immunocompromised patients. The oral suspension is approved for treating oropharyngeal candidiasis, including cases resistant to itraconazole or fluconazole in patients 13 and older.
Mylan Institutional LLC
Usage: Posaconazole injection is indicated for treating invasive aspergillosis in patients aged 13 and older and for prophylaxis against invasive Aspergillus and Candida infections in severely immunocompromised patients, including those with graft-versus-host disease or prolonged neutropenia from chemotherapy, starting at age 2.

Vfend (voriconazole)

(Voriconazole)
Roerig
Usage: VFEND is indicated for treating invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and serious fungal infections caused by Scedosporium and Fusarium species in adults and pediatric patients (2 years and older) intolerant to or refractory to other therapies.
Sandoz Inc
Usage: Voriconazole tablets are indicated for the treatment of invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and serious fungal infections caused by Scedosporium and Fusarium species in patients aged 2 years and older, particularly those intolerant or refractory to other therapies.
Greenstone LLC
Usage: Voriconazole is indicated for treating invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. in patients 2 years and older who are intolerant or refractory to other therapies.
Slate Run Pharmaceuticals
Usage: Voriconazole for injection is indicated for adults and pediatric patients (2 years and older) to treat invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium species, especially when other therapies are ineffective or intolerable.